Biomarker for liver cancer diagnosis and detection kit

A biomarker and kit technology, applied in the field of medicine and biology, can solve the problems of less than 12% survival rate, non-specific early symptoms, limited treatment methods for hepatocellular carcinoma, etc., and achieve good differentiation and diagnosis effects Effect

Active Publication Date: 2022-03-01
ZHENGZHOU UNIV
View PDF24 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the early symptoms are not specific and easy to be ignored, and the sensitivity of the current clinically used AFP in diagnosing hepatocellular carcinoma is only 60%, most of the patients with hepatocellular carcinoma are already in the middle and late stages when they are diagnosed
In addition, because the current treatment options for HCC are very limited, the prognosis of patients is poor, and the overall 5-year survival rate is less than 12%.
[0004] At present, there are relatively few studies on autoantibodies that can be used for the diagnosis of liver cancer. In order to improve the efficiency of early diagnosis of liver cancer and improve the survival rate of patients with liver cancer, it is urgent to screen more serological autoantibody markers that can be used for the diagnosis of liver cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for liver cancer diagnosis and detection kit
  • Biomarker for liver cancer diagnosis and detection kit
  • Biomarker for liver cancer diagnosis and detection kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: Screening markers for diagnosis of liver cancer using human proteome chip

[0044] 1. Experimental sample:

[0045] Sera from 30 patients with liver cancer (liver cancer group) and 24 normal controls (normal control group) were collected from the specimen bank of the Key Laboratory of Cancer Epidemiology in Henan Province; Liver cancer patients without any treatment; 24 cases of normal human serum were obtained from healthy subjects. The inclusion criteria for healthy subjects were: no cardiovascular, respiratory, liver, kidney, gastrointestinal tract, endocrine, blood, mental, or Nervous system diseases and medical history of the above diseases, no acute or chronic diseases, no autoimmune diseases, no evidence of any tumor-related; moreover, there is no statistically significant difference between sexes in 30 patients with liver cancer and 24 healthy subjects . This study was approved by the Ethics Committee of Zhengzhou University, and all subjects had si...

Embodiment 2

[0065] Example 2: ELISA detection of serum expression levels of autoantibodies against tumor-associated antigens ZIC2, CDC37L1, PCNA, and MAP3K14

[0066] Indirect enzyme-linked immunosorbent assay (enzyme linked immunosorbent assay, ELISA) was used to further detect the expression levels of the four anti-tumor-associated antigen autoantibodies screened in Example 1 in the serum of a large sample of people.

[0067]1. Experimental sample:

[0068] The 296 hepatocellular carcinoma patients (liver cancer group), 296 liver cirrhosis patients (liver cirrhosis group) and 296 normal control serum samples (normal control group) included in this study were all obtained from the Henan Provincial Key Laboratory of Tumor Epidemiology library. The serum of 296 hepatocellular carcinoma patients was obtained from hepatocellular carcinoma patients diagnosed by pathology and without any treatment, of which 91 patients with hepatocellular carcinoma were in the early stage (BCLC stage 0-B); th...

Embodiment 3

[0103] Example 3: Evaluation of the ability of four anti-tumor-associated antigen autoantibodies for liver cancer diagnosis

[0104]The serum of 296 patients with hepatocellular carcinoma and 296 normal controls included in Example 2 was randomly divided into a training set and a verification set in a ratio of 6:4; wherein, 176 patients with hepatocellular carcinoma were included in the training set (referred to as the liver cancer group) , 176 cases of normal controls (denoted as normal control group); 120 cases of hepatocellular carcinoma patients and 120 cases of normal controls in the validation set.

[0105] According to the results of the expression levels of anti-tumor-associated antigen ZIC2, CDC37L1, PCNA, and MAP3K14 autoantibodies in each serum sample in the training set detected by ELISA in Example 2, GraphPad Prism 8.0 was used to draw single anti-tumor-associated antigen autoantibodies, multiple anti-tumor-associated antigen autoantibodies, and Combined diagnosis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of medical biology, and particularly discloses a biomarker for ovarian cancer diagnosis and a detection kit. The biomarker for liver cancer diagnosis provided by the invention is at least one of autoantibodies of anti-tumor related antigens ZIC2, CDC37L1, PCNA and MAP3K14, the expression level of the marker in serum of a liver cancer patient is higher than that of a normal person, and the difference has statistical significance. The invention also provides a kit for liver cancer diagnosis, the kit contains a reagent for detecting the biomarker, and the reagent is used for detecting the biomarker in a sample through enzyme-linked immunosorbent assay, a protein chip, immunoblotting or microfluidic immunoassay. By detecting the expression level of the biomarker in human serum, liver cancer patients and healthy people can be effectively distinguished, and the biomarker can be used for auxiliary diagnosis of liver cancer.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and specifically discloses a biomarker and a detection kit for liver cancer diagnosis. Background technique [0002] Hepatocellular carcinoma is the second leading cause of cancer death in the world, and the incidence and mortality of hepatocellular carcinoma in China are the highest in the world. Global cancer epidemiological statistics show that in 2020, there will be 905,000 new cases of hepatocellular carcinoma and 830,000 deaths due to hepatocellular carcinoma. The mortality rate of hepatocellular carcinoma ranks second in malignant tumors. Because the early symptoms are not specific and easy to be ignored, and the sensitivity of the currently used AFP for diagnosing hepatocellular carcinoma is only 60%, most patients with hepatocytes are already in the middle and late stages when they are diagnosed. In addition, due to the currently very limited treatment options for hepatocellular car...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68
CPCG01N33/57438G01N33/57488G01N33/6854G01N2469/20G01N2333/47
Inventor 叶华仵金玉邱翠鹏王鹏史建翔王科妍杨倩骆焕代丽萍
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap